We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Drugs Less Effective Than Lifestyle Modifications in Increasing HDL

By Biotechdaily staff writers
Posted on 05 Sep 2007
A recently published review article suggested that lifestyle modifications were more successful in raising high-density lipoprotein (HDL) levels than most available drug treatments.

Nearly 40% of all heart attacks and related cardiovascular problems occur in individuals with low HDL levels. More...
Those with blood levels of HDL lower than 35 mg/dl (16-18% of men and 3- 6% of women) have eight times the risk of heart disease compared to those with 65 mg/dl or more. Thus, finding drug treatments to raise the level of HDL has become of major interest.

A team of investigators reviewed the literature related to attempts to raise HDL levels and compared results from lifestyle modification (dieting, exercise, etc.) to those from various drug treatments. Results of the review of 31 randomized controlled trials published in the August 15, 2007, issue of the Journal of the American Medical Association revealed that several lifestyle modifications were effective in increasing HDL. Among these lifestyle modifications were weight loss, exercise, smoking cessation, moderate alcohol consumption, and eating fish or taking fish oil to increase intake of omega-3 fatty acids.

As for pharmacologic approaches, the study found that the most effective currently available drug to raise HDL is the vitamin niacin, taken in high doses. "Statins, niacin, and fibrates are available pharmacological agents that increase HDL; however, they may be associated with adverse side effects,” said contributing author Dr. Mehdi Shishehbor from the Cleveland Clinic (OH, USA).

"Despite the recent negative HDL trials, this field is extremely exciting and the pace of discovery is unbelievably fast,” Dr. Shishehbor said. "At least one other drug with a novel mechanism of action is also in trials--and at least three other approaches have led to new drugs in the pipeline.”


Related Links:
Cleveland Clinic

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Radiofrequency Generator
GX1
New
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.